Merck (MRK) Turns Heads With Phase 3 Endometrial Cancer Data And FDA Review

• Merck (NYSE:MRK) reported new Phase 3 data at ESMO 2026 showing KEYTRUDA monotherapy benefits in advanced endometrial cancer.

• Sacituzumab tirumotecan delivered positive outcomes in a separate late stage trial for recurrent endometrial cancer presented at the same congress.

• The Lancet published the full trial results and the FDA granted priority review to the sacituzumab tirumotecan Biologics License Application.

• These KEYTRUDA and sacituzumab tirumotecan advances in endometrial cancer matter, but investors need a wider Merck view too. Check out 5 warning signs that Merck investors should know about.

This push into advanced endometrial cancer is part of a broader oncology shift, and other players tied to this theme sit inside 36 healthcare AI stocks .

Merck is a global pharmaceuticals group based in GB with a reported market value of about $349.9b, and oncology sits alongside other healthcare franchises as a major pillar of its worldwide business. Progress in advanced endometrial cancer adds another high profile program to that broader treatment portfolio.

2 things going right for Merck that this headline doesn't cover.

How do these KEYTRUDA and sacituzumab tirumotecan results change Merck's oncology opportunity?

The two Phase 3 readouts give Merck data in both front line dMMR advanced endometrial cancer with KEYTRUDA and post immunotherapy disease with sacituzumab tirumotecan. That pushes the group deeper into a women's cancer segment where options have been limited. It also adds another antibody drug conjugate alongside its existing immunotherapy portfolio, which can broaden where Merck competes.

Does this endometrial cancer news shift the Merck Narrative investors have been using?

The Narrative hinges on Merck turning late stage programs such as sac TMT and its wider oncology pipeline into durable franchises that help offset future KEYTRUDA loss of exclusivity. TroFuse 005 data plus the FDA priority review directly support that thesis by backing sacituzumab tirumotecan with survival benefit and regulatory momentum in a defined setting.

See how these catalysts shape Merck's path to a $160 fair value .

What should Merck investors watch next off the back of these trials?

The clearest marker to track is the U.S. FDA's priority review for sacituzumab tirumotecan, which has a target action date of June 15, 2027. The eventual label scope, any boxed warnings and how often management references the drug in guidance updates will shape expectations for its revenue contribution inside Merck's broader oncology mix.